Company profile
StateHouse Holdings Inc.
OTC: STHZF · Healthcare · Drug Manufacturers - Specialty & Generic
#351 of 1,422 Healthcare companies by revenue34th-percentile growth
EA Score
——FH —DQ —GM —SS 43
v0.1 · 5/100 weight · pillars only
↑ workforce scale, Piotroski F · ↓ market scale, balance-sheet leverage
Methodology →Revenue TTM
$104.0M
Rev growth YoY (TTM)
-0.6%
Net income (FY)
-$49.9M
Employees
323
as of 2026-08-29
Market cap
$35.6k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$100.5M$100.5M2023
Net income-$49.9M-$49.9M2023
Operating income-$12.2M-$12.2M2023
Total assets$123.1M$123.1M2023
Liabilities$284.8M$284.8M2023
Equity-$162.0M-$162.0M2023
Revenue trend
FY2016 – FY2023 · USD
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is StateHouse Holdings Inc.’s revenue?
StateHouse Holdings Inc. booked $100.5M in FY2023 revenue, contracting 7.1% year over year — slower than 66% of Healthcare companies we track, at a -49.6% net margin.
Peers · Healthcare
Sanara MedTech Inc.61CSutro Biopharma, Inc.47DViewRay, Inc.——Beta Bionics, Inc.58CNeuroPace, Inc.53DMedexus Pharmaceuticals Inc.64CNeighbors
San Diego →Key facts
CEOEdward Schmults
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersSan Diego, CA
ExchangeOTC: STHZF
Employees323
IPO date2019-06-12
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.